- Home
- THAR vs GLMD Comparison
THAR vs GLMD Comparison
Compare THAR & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THAR
- GLMD
- Stock Information
- Founded
- THAR 2017
- GLMD 2000
- Country
- THAR United States
- GLMD Israel
- Employees
- THAR N/A
- GLMD N/A
- Industry
- THAR Biotechnology: Pharmaceutical Preparations
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- THAR Health Care
- GLMD Health Care
- Exchange
- THAR Nasdaq
- GLMD Nasdaq
- Market Cap
- THAR 3.3M
- GLMD 3.0M
- IPO Year
- THAR 2022
- GLMD 2014
- Fundamental
- Price
- THAR $1.82
- GLMD $1.81
- Analyst Decision
- THAR Strong Buy
- GLMD Hold
- Analyst Count
- THAR 1
- GLMD 1
- Target Price
- THAR $17.00
- GLMD N/A
- AVG Volume (30 Days)
- THAR 41.7K
- GLMD 364.3K
- Earning Date
- THAR 08-08-2025
- GLMD 05-22-2025
- Dividend Yield
- THAR N/A
- GLMD N/A
- EPS Growth
- THAR N/A
- GLMD N/A
- EPS
- THAR N/A
- GLMD N/A
- Revenue
- THAR N/A
- GLMD N/A
- Revenue This Year
- THAR N/A
- GLMD N/A
- Revenue Next Year
- THAR N/A
- GLMD N/A
- P/E Ratio
- THAR N/A
- GLMD N/A
- Revenue Growth
- THAR N/A
- GLMD N/A
- 52 Week Low
- THAR $0.95
- GLMD $1.15
- 52 Week High
- THAR $6.39
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- THAR 64.36
- GLMD 61.13
- Support Level
- THAR $1.30
- GLMD $1.63
- Resistance Level
- THAR $1.46
- GLMD $1.94
- Average True Range (ATR)
- THAR 0.14
- GLMD 0.12
- MACD
- THAR 0.02
- GLMD 0.01
- Stochastic Oscillator
- THAR 96.17
- GLMD 69.77
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.